JP2021522801A5 - - Google Patents
Info
- Publication number
- JP2021522801A5 JP2021522801A5 JP2020561908A JP2020561908A JP2021522801A5 JP 2021522801 A5 JP2021522801 A5 JP 2021522801A5 JP 2020561908 A JP2020561908 A JP 2020561908A JP 2020561908 A JP2020561908 A JP 2020561908A JP 2021522801 A5 JP2021522801 A5 JP 2021522801A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- fragment
- sequence
- cdrs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024059296A JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668824P | 2018-05-09 | 2018-05-09 | |
| US62/668,824 | 2018-05-09 | ||
| PCT/IL2019/050508 WO2019215728A1 (en) | 2018-05-09 | 2019-05-06 | Antibodies specific to human nectin4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059296A Division JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522801A JP2021522801A (ja) | 2021-09-02 |
| JP2021522801A5 true JP2021522801A5 (enExample) | 2022-05-13 |
Family
ID=66690730
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561908A Pending JP2021522801A (ja) | 2018-05-09 | 2019-05-06 | ヒトネクチン４に特異的な抗体 |
| JP2024059296A Pending JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059296A Pending JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12077583B2 (enExample) |
| EP (1) | EP3790900A1 (enExample) |
| JP (2) | JP2021522801A (enExample) |
| KR (2) | KR102892725B1 (enExample) |
| CN (2) | CN112088167B (enExample) |
| AU (1) | AU2019264965B2 (enExample) |
| CA (1) | CA3097679A1 (enExample) |
| IL (1) | IL277858B1 (enExample) |
| WO (1) | WO2019215728A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| CN113527486B (zh) * | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| CA3176497A1 (en) | 2020-05-07 | 2021-11-11 | Fatima MECHTA-GRIGORIOU | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| CN115768798A (zh) * | 2020-06-18 | 2023-03-07 | 生物蛋白有限公司 | 条件活性抗粘附分子-4(nectin-4)抗体 |
| EP4208259A2 (en) * | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| CN117285629A (zh) * | 2020-09-16 | 2023-12-26 | 四川科伦博泰生物医药股份有限公司 | 抗Nectin-4抗体、包含所述抗体的缀合物及其应用 |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| BR112023022098A2 (pt) * | 2021-04-26 | 2023-12-19 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anticorpo anti-nectina-4 e conjugado anticorpo-fármaco anti-nectina-4 e uso medicinal dos mesmos |
| EP4363453A4 (en) * | 2021-06-29 | 2025-06-11 | Elpis Biopharmaceuticals | ANTI-NECTIN4 ANTIBODIES AND MULTISPECIFIC PROTEIN COMPLEXES |
| CA3227845A1 (en) * | 2021-07-30 | 2023-02-02 | R.P. Scherer Technologies, Llc | Antibody-drug conjugates and methods of use thereof |
| AU2022335573C1 (en) * | 2021-08-27 | 2026-02-19 | CSPC Megalith Biopharmaceutical Co., Ltd. | Anti-nectin-4 antibody, drug conjugate, and preparation method therefor and use thereof |
| CA3242471A1 (en) * | 2022-01-12 | 2023-07-20 | Navi Bio-Therapeutics, Inc. | Antibody specific to nectin cell adhesion molecule 4 and uses thereof |
| EP4496593A1 (en) | 2022-03-23 | 2025-01-29 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| WO2023198007A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Anti-nectin-4 antibodies and bispecific antibodies |
| WO2023198011A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Single domain anti-nectin-4 antibodies |
| CN116063498A (zh) * | 2022-04-27 | 2023-05-05 | 博际生物医药科技(杭州)有限公司 | 单域抗Nectin-4抗体 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| US20260091114A1 (en) * | 2022-09-14 | 2026-04-02 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
| US20260014269A1 (en) | 2022-09-20 | 2026-01-15 | Nectin Therapeutics Ltd. | Humanized antibodies against nectin-4 and drug conjugates thereof |
| AU2023375625A1 (en) * | 2022-11-10 | 2025-05-15 | Century Therapeutics, Inc. | Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof |
| EP4646267A1 (en) * | 2023-01-03 | 2025-11-12 | Harpoon Therapeutics, Inc. | Nectin4 targeting trispecific protein for treatment of cancer |
| CN116381251B (zh) * | 2023-03-13 | 2024-06-25 | 柏定生物工程(北京)有限公司 | 一种肿瘤标志物诊断试剂盒及其诊断方法 |
| JP2026512425A (ja) | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| EP4687990A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| CN119490590A (zh) * | 2023-05-24 | 2025-02-21 | 深圳市先康达生命科学有限公司 | 靶向人Nectin4蛋白的抗体或其片段和应用 |
| EP4725964A1 (en) * | 2023-06-08 | 2026-04-15 | Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. | Antibody binding to nectin-4 and use thereof |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025240789A1 (en) * | 2024-05-16 | 2025-11-20 | The Regents Of The University Of California | Chimeric antigen receptor targeting nectin4 |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198507A (en) | 1978-11-13 | 1980-04-15 | Hoffmann-La Roche Inc. | Theophylline magnesium salicylate |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| ES2102007T3 (es) | 1992-01-23 | 1997-07-16 | Merck Patent Gmbh | Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras. |
| JP3659261B2 (ja) | 1994-10-20 | 2005-06-15 | モルフォシス・アクチェンゲゼルシャフト | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| ATE274064T1 (de) | 1995-05-23 | 2004-09-15 | Morphosys Ag | Multimere proteine |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| EP1103181A1 (de) | 1999-11-25 | 2001-05-30 | Novartis AG | Kombination der N-Phenyl-N'-Benzoyl Harnstoff Derivaten und Avermectin für Parasiten Kontrolle. |
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| US20090214517A1 (en) | 2004-07-27 | 2009-08-27 | Justin Wong | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease |
| CA2672581A1 (en) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| US9399062B2 (en) * | 2011-01-18 | 2016-07-26 | Christopher D. Richardson | PVRL4 (Nectin4) is a receptor for measles virus |
| AU2013355379B2 (en) | 2012-12-04 | 2018-08-09 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| CR20170060A (es) | 2014-08-19 | 2017-04-18 | Merck Sharp & Dohme | Anticuerpos anti tigit |
| SG11201706583PA (en) | 2015-02-19 | 2017-09-28 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| EP3344658B1 (en) | 2015-09-02 | 2022-05-11 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Antibodies specific to human t-cell immunoglobulin and itim domain (tigit) |
| EP3347048B1 (en) | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| KR20250065434A (ko) | 2016-03-01 | 2025-05-12 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체 |
| EP3589654A1 (en) | 2017-03-02 | 2020-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| WO2022056304A1 (en) | 2020-09-10 | 2022-03-17 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using nectin-4 specific fusion proteins |
-
2019
- 2019-05-06 WO PCT/IL2019/050508 patent/WO2019215728A1/en not_active Ceased
- 2019-05-06 KR KR1020207031656A patent/KR102892725B1/ko active Active
- 2019-05-06 CN CN201980029788.XA patent/CN112088167B/zh active Active
- 2019-05-06 CA CA3097679A patent/CA3097679A1/en active Pending
- 2019-05-06 IL IL277858A patent/IL277858B1/en unknown
- 2019-05-06 US US17/052,960 patent/US12077583B2/en active Active
- 2019-05-06 KR KR1020257039502A patent/KR20250173584A/ko active Pending
- 2019-05-06 JP JP2020561908A patent/JP2021522801A/ja active Pending
- 2019-05-06 CN CN202411898788.2A patent/CN119823267A/zh active Pending
- 2019-05-06 AU AU2019264965A patent/AU2019264965B2/en active Active
- 2019-05-06 EP EP19728137.1A patent/EP3790900A1/en active Pending
-
2024
- 2024-04-02 JP JP2024059296A patent/JP2024088696A/ja active Pending
- 2024-07-23 US US18/780,731 patent/US20240376202A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016281641B2 (en) | Novel PD-1 immune modulating agents | |
| JP2019511212A5 (enExample) | ||
| AU2019264965B2 (en) | Antibodies specific to human Nectin4 | |
| JP2022519341A5 (enExample) | ||
| JP2022515487A5 (enExample) | ||
| JP2021527431A5 (enExample) | ||
| JP2021531764A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2018532383A5 (enExample) | ||
| RU2018134065A (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| JP2019533719A5 (enExample) | ||
| JP2020527332A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| CN108348521A (zh) | 用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺 | |
| FI3941946T3 (fi) | Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja | |
| JP2013519367A5 (enExample) | ||
| JP2022553922A5 (enExample) | ||
| JP2021512107A5 (enExample) | ||
| JP2021520201A5 (enExample) | ||
| JP2015509960A5 (enExample) | ||
| JP2021533796A5 (enExample) | ||
| JP2022512713A5 (enExample) | ||
| JP2025148452A5 (enExample) |